Potential of the Transdermal Drug Delivery Systems for the Topical Treatment of Chronic Venous Diseases

Savel’eva M.I.; Sychev D.A.

doi:https://doi.org/10.17116/flebo201812140-49

Savel’eva M.I.

Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russia, Moscow, Russia

Sychev D.A.

Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russia, Moscow, Russia

Potential of the Transdermal Drug Delivery Systems for the Topical Treatment of Chronic Venous Diseases

Authors:

Savel’eva M.I., Sychev D.A.

More about the authors

Journal: Journal of Venous Disorders. 2018;12(1): 40‑49

DOI: 10.17116/flebo201812140-49

Read: 8173 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Savel’eva MI, Sychev DA. Potential of the Transdermal Drug Delivery Systems for the Topical Treatment of Chronic Venous Diseases. Journal of Venous Disorders. 2018;12(1):40‑49. (In Russ.)
https://doi.org/10.17116/flebo201812140-49

Подписка 2026 Флебология (Journal of Venous Disorders)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Objective Monitoring of Compliance with Compression Treatment in Patients with Chronic Venous Disease is Better than Self-Reported Using Patient’s Diary. Journal of Venous Disorders. 2025;(2):113-119

Clinical Decisions in the Absence of Evidence: Expert’s Panel Recommendations for the Management of Chronic Venous Disease and Superficial Thrombophlebitis. Journal of Venous Disorders. 2025;(2):126-140

Onset, Time Course and Duration of Venoactive Drugs Effect on Venous Symptoms in Patients with Chronic Venous Disease. Journal of Venous Disorders. 2025;(3):206-215

Predictors of Venous Symptoms Improvement in Chronic Venous Disease Patients on Compression Therapy. Journal of Venous Disorders. 2025;(4):250-256

A Topical Agent Based on Recombinant Human Epidermal Growth Factor and Silver Sulfadiazine Accelerates the Healing of Venous (Chronic) Ulcers: A Prospective Comparative Non-Randomized Study ESKIZ. Journal of Venous Disorders. 2025;(4):284-294

Diosmin and Other Venoactive Drugs: Mechanisms of Action, Current and Future Indications for Use. Journal of Venous Disorders. 2025;(4):307-314

Groin Soft Tissue Leiomyosarcoma or Femoral Vein Leiomyosarcoma?. Journal of Venous Disorders. 2025;(4):316-319

Abstract:

The objective of this review was to discuss the problems related to the use of the systems designed for the transdermal delivery of the medications in the patients presenting with chronic venous disease and the approaches to the solution of these problems in the framework of modern clinical pharmacology. The processes of percutaneous absorption of drugs are considered in detail. The transdermal delivery systems are classified, and the mechanisms underlying the functioning of the self-organizing liposomal transdermal systems on a gel basis are described with special reference to the role of absorption enhancers. The place and the role of topical drugs in the treatment of chronic venous disease according to the current clinical recommendations are characterized. The classification and ranking of topical agents according to the degree of expression of their pharmacodynamic effects are presented, their similarities and differences are demonstrated. The constituent components of Detragel (a combination of aescin, essential phospholipids, and heparin sodium) are considered with the special emphasis placed on their pharmacodynamic and pharmacokinetic properties. The results of the clinical studies showing the advantages of this combination over other agents for the treatment of chronic venous diseases are presented. It is concluded that the application of the topical combined drugs for the treatment of chronic venous disease helps to reduce the severity of its clinical manifestations and to solve certain problems associated with the prescription of the systemic agents. It is concluded that the application of the topical combinations of relevant medications used for the treatment of chronic venous disease facilitates the solution of the complicated problems facing their therapy and provides a basis for the use of pharmaceutical products possessed of systemic action.

Keywords:

transdermal delivery systems

liposomes

essential phospholipids

chronic venous disease

Authors:

Savel’eva M.I.

Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russia, Moscow, Russia

Sychev D.A.

Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russia, Moscow, Russia

Close metadata

References:

Vasil’ev AE, Krasnyuk II, Ravikumar C, Tokhmakhchy VN. Transdermal therapeutic systems for controlled drug release (a review). Pharmaceutical Chemistry Journal. 2001;35(11):613-626. (In Russ.) https://doi.org/10.1023/a:1015149911917
The Top 40 Transdermal Drug Delivery Technology Companies Worldwide. Accessed: October 21-nd 2017. http://www.researchandmarkets.com
Prausnitz MR, Langer R, Transdermal Drug Delivery. Nature biotechnology. 2008;(26);11:1261-1268. https://doi.org/10.1038/nbt.1504
Riviere JE. Comparative pharmacokinetics: principles, techniques, and applications. 2-nd edition. John Wiley and Sons, Inc. 2011. https://doi.org/10.1002/9780470959916
Tanner T, Marks R. Delivering drugs by the transdermal route: review and comment. Skin Research and Technology. 2008;14:249-260. https://doi.org/10.1111/j.1600-0846.2008.00316.x
Keservani RK, Sharma AK, Kesharwani RK. Novel approaches for drug delivery: Monograph. Advances in Medical Technologies and Clinical Practice. IGI Global, 2017. https://doi.org/10.4018/978-1-5225-0751-2
Mahato RI, Narang AS. Pharmaceutical dosage forms and drug delivery. CRC Press. 2007;336. https://doi.org/10.1177/875512250802400415
Chueshov VI, Chernov MJ, Khohlova LM. Promyshlennaya tekhnologia lekarstv. Uchebnik. V. 2. Pod red Chueshov V.I. MTK-book: NFAU, 2002 (In Russ.)
Krylov YuF, Bobyrev VM. Pharmacologia. M.: VHNMC, 1999 (In Russ.)
Dragicevic N, Maibach HI. (eds.). Percutaneous penetration enhancers chemical methods in penetration enhancement: nanocarriers. Berlin—Heidelberg: Springer-Verlag, 2016. https://doi.org/10.1007/978-3-662-47862-2
Pawlikowska-Pawlega B, Misiak LE, Zarzyka B, Paduch R, Gawron A, Gruszecki WI. FTIR, (1) H NMR and EPR spectroscopy studies on the interaction of flavone apigenin with dipalmitoylphosphatidylcholine liposomes. Biochim Biophys Acta. 2012;1828;518-527. https://doi.org/10.1016/j.bbamem.2012.10.013
Tarahovsky YuS, Kim JA, Abdrasilov BS, Muzafarov EN. (otv. red. Maevsky EI. Flavonoidy: biohimia, biofizika, medicina. Puschino: Synchrobook, 2013. (In Russ.)
Savelyeva MI. Vsasyvanie lekarstvennyh sredstv. Clinicheskaya Pharmacokinetica. Pod red. Kukes VG. M. 2008;gl. 3:12-27. (In Russ.)
Thomas BJ, Finnin BC. The transdermal revolution. Drug Discovery Today, 2004;16(9):697-703. https://doi.org/10.1016/s1359-6446(04)03180-0
Calculator molar massy. Accessed: October 21-nd 2017. (In Russ.) https://www.translatorscafe.com/unit-converter/ru/molar-mass/1-1/
Betz G, Nowbakht P, Imboden R, Imanidis G. Heparin penetration into and permeation through human skin from aqueous and liposomal formulations in vitro. International Journal of Pharmaceutics. 2001;228:147-159. https://doi.org/10.1016/s0378-5173(01)00832-8
Sapelkin SV. Vozmozhnosti primenenia topicheskih sredstv pri lechenii hronicheskih zabolevaniy ven (HZV). Hirurgia. Prilozhenie k zhurnalu Consilium Medicum. 2009;1:61-63 (In Russ.)
Ruckley CV, Evans CJ, Allan PL, Lee AJ, Fowkes FGR. Teleangiectasia in the Edinburgh Vein study: epidemiology and association with trunk varices and symptoms. Eur J Vasc Endovasc Surg. 2008;36:719-724. https://doi.org/10.1016/j.ejvs.2008.08.012
Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. International Angiology. 2007;26:1-59. https://doi.org/10.1007/978-81-322-1991-0_11
Sirtori CR. Aescin: Pharmacology, Pharmacokinetics and Therapeutic Profile. Pharmaceutical Research. 2001;44(3):183-193. https://doi.org/10.1006/phrs.2001.0847
Wetzel D, Menke W, Dieter R, Smasal V, Gianetti B, Bulitta M. Escin/diethylammonium salicylate/heparin combination gels for the topical treatment of acute impact injuries: a randomised, double blind, placebo controlled, multicentre study. Br J Sports Med. 2002 Jun;36(3):183-188. https://doi.org/10.1136/bjsm.36.3.183
Pittler MH, Ernst E. Horse-Chestnut seed extract for chronic venous insufficiency. Arch Dermatol. 1998;134:1356-1360. https://doi.org/10.1001/archderm.134.11.1356
Luzzi R, Feragalli B, Belcaro G, Cesarone MR, Cornelli U, Dugall M, Hosoi M. Aescin: microcirculatory activity. Effects of accessory components on clinical and microcirculatory efficacy. Panminerva Med. 2011;53(3 Suppl 1):51-55.
Shvarts GYa. Sovremennye nesteroidnye protivovospalitelnye preparaty: Monografia. M: Reapharm, 2004;5-9. (In Russ.)
Vorobyova OV. Rol’ nesteroidnyh protivovospalitelnyh preparatov v terapii boley v spine. Medicinskaya kafedra. 2015;3(15):1-8. (In Russ.)
Nieman DC, Haig JL, Fairchild KS, De Guia ED, Dizon GP, Register UD. Reducing-diet and exercise-training effects on serum lipids and lipoproteins in mildly obese women. Am J Clin Nutr. 1990 Oct;52:4:640-645. https://doi.org/10.1055/s-2007-1024730
Martindale/MICROMEDEX. Heparin. Healthcare Series for Windows. Micromedex Thomson Healthcare. 2013. https://doi.org/10.21019/ale.1000.146
Belcaro G, Nicolaides A, Geroulakos G. Essaven gel-review of experimental and clinical data. Angiology. 2001;52(Suppl 3):SI-S4. https://doi.org/10.1177/0003319701052003s02
Belcaro G, Cesarone M, Dugall M. Microcirculatory efficacy of topical treatment with aescin + essential phospholipids gel in venous insufficiency and hypertension: new clinical observations. Angiology. 2004;55:Sl-S5. https://doi.org/10.1177/000331970405500601
Wojcicki J, Samochowiec L, Lawczyski L, Dabrowski Z. Local treatment of thrombophlebitis with Essaven gel. Arch Immunol Ther Exp. 1976;24(6): 807-810.
Cesarone MR, De Sanctis MT, Incandela L, Belcaro G, Griffin M. Microvascular changes in venous hypertension due to varicose veins after standardized application of Essaven gel: a placebo-controlled, randomized study. Angiology. 2001 Dec;52(Suppl. 3):S11-S16. https://doi.org/10.1177/0003319701052003s04
Incandela L, Belcaro G, Cesarone MR, De Sanctis MT, Griffin M. Changes in microcirculation in venous ulcers with Essaven gel: a pilot, cross-over, placebo-controlled, randomized study. Angiology. 2001 Dec;52(Suppl. 3):S23-S27. https://doi.org/10.1177/0003319701052003s06
De Sanctis MT, Incandela L, Belcaro G, Cesarone MR. Topical treatment of venous microangiopathy in patients with venous ulceration with Essaven gel: a placebo-controlled, randomized study. Angiology. 2001 Dec;52(Suppl. 3):S29-S34. https://doi.org/10.1177/0003319701052003s07
Inga C, Pignocchino P, Casini A. Clinical evaluation of a gel with a high heparin content. Minerva Angiolog. 1985;10(3):247-249.
EMEA (European Medicines Agency). Assessment Report On Aesculus Hippocastanum L, Semen. Accessed: June 22nd 2010. http://www.ema.europa.eu/pdfs/human/hmpc/hippocastani semen/22530408 en.pdf
Vecchio C, Frisinghelli A. Topically applied heparins for the treatment of vascular disorders. A comprehensive review. Clin Drug Invest. 2008;28(10): 603-614. https://doi.org/10.2165/00044011-200828100-00001